Quotables
"What can be more palpably absurd than the prospect held out of locomotives traveling twice as fast as stagecoaches?"
The Quarterly Review ; March edition, 1825
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7151095 | Immunoregulatory compounds and derivatives and methods of treating diseases therewith Compounds are disclosed having the structure of Formula I: where R1, R3, and R4 are independently hydrogen or C1 to C4 alkyl, and R2 is: | 12/19/2006 |
| 7119162 | Substantially monodispersed mixtures of polymers having polyethylene glycol moieties Methods of synthesizing a substantially monodispersed mixture of polymers comprising polyethylene glycol moieties include: reacting a substantially monodispersed mixture of compounds having the structure of Formula I: R | 10/10/2006 |
| 7119074 | Treatment of cancers, tumors and malignancies using amphiphilic prodrugs The present invention provides amphiphilic prodrugs comprising a therapeutic compound conjugated to an PEG-oligomer/polymer and methods for using said prodrugs to enable oral drug delivery and/or delivery of drugs across the blood brain barrier into the central nerv... | 10/10/2006 |
| 7084114 | Mixtures of insulin drug-oligomer comprising polyalkylene glycol A mixture of conjugates in which each conjugate in the mixture comprises an insulin drug coupled to an oligomer that includes a polyalkylene glycol moiety is disclosed. The mixture may exhibit higher in vivo activity than a polydispersed mixture of similar conjugate... | 08/01/2006 |
| 7084121 | Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same A mixture of conjugates in which each conjugate in the mixture comprises a calcitonin drug coupled to an oligomer that includes a polyalkylene glycol moiety is disclosed. The mixture may lower serum calcium levels in a subject by 10, 15 or even 20 percent or more. M... | 08/01/2006 |
| 7060675 | Methods of treating diabetes mellitus Methods of treating diabetes mellitus in a patient in need of such treatment include administering an effective amount of an insulin drug to the patient in order to treat diabetes mellitus in the patient. Methods according to the present invention may “activate”... | 06/13/2006 |
| 7030082 | Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith Pharmaceutical compositions that include a drug and/or drug-oligomer conjugate, a fatty acid component and a bile salt component, or a bile salt component without a fatty acid component are described. The drug can be covalently coupled to an oligomeric moiety. The f... | 04/18/2006 |
| 7030084 | Drug-oligomer conjugates with polyethylene glycol components The present invention relates generally to hydrolyzable drug-oligomer conjugates, pharmaceutical compositions comprising such conjugates, and to methods for making and using such conjugates and pharmaceutical compositions. For example, a conjugate of insulin, PEG, a... | 04/18/2006 |
| 7022869 | Methods of asymmetrically synthesizing enantiomers of casodex, its derivatives and intermediates thereof Methods of synthesizing pure enantiomers of acylanalides such as Casodex® (bicalutamide) and its derivatives utilizing a compound having a ring structure that, when opened, provides a substituent having the structure of Formula I: | 04/04/2006 |
| 6956051 | Enkephalin conjugates The present invention relates to amphiphilic drug-oligomer conjugates capable of traversing the blood-brain barrier (“BBB”) and to methods of making and using such conjugates. An amphiphilic drug-oligomer conjugates comprise a therapeutic compound conjugated to ... | 10/18/2005 |
| 6943148 | Methods for delivering therapeutics across blood-barrier and for altering receptor binding affinity The present invention relates to amphiphilic drug-oligomer conjugates capable of traversing the blood-brain barrier (“BBB”) and to methods of making and using such conjugates. An amphiphilic drug-oligomer conjugates comprise a therapeutic compound conjugated to ... | 09/13/2005 |
| 6930090 | Methods of activating a receptor using amphiphilic drug-oligomer conjugates The present invention relates to amphiphilic drug-oligomer conjugates capable of traversing the blood-brain barrier (“BBB”) and to methods of making and using such conjugates. An amphiphilic drug-oligomer conjugate comprises a therapeutic compound conjugated to ... | 08/16/2005 |
| 6913903 | Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same Methods for synthesizing proinsulin polypeptides are described that include a contacting a proinsulin polypeptide including an insulin polypeptide coupled to one or more peptides by peptide bond(s) capable of being cleaved to yield the insulin polypeptide with an ol... | 07/05/2005 |
| 6903082 | Methods of treating inflammatory conditions of the gastrointestinal tract using 4-APAA and compositions thereof Compounds are disclosed having the structure of Formula I: where R1, R3, and R4 are independently hydrogen or C1 to C4 alkyl, and R2 is: | 06/07/2005 |
| 6867183 | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith Pharmaceutical compositions that include an insulin drug-oligomer conjugate, a fatty acid component, and a bile salt component are described. The insulin drug is covalently coupled to an oligomeric moiety. The fatty acid component and the bile salt component are pre... | 03/15/2005 |
| 6858580 | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same A non-polydispersed mixture of conjugates in which each conjugate in the mixture comprises a drug coupled to an oligomer that includes a polyalkylene glycol moiety is disclosed. The mixture may exhibit higher in vivo activity than a polydispersed mixture of similar ... | 02/22/2005 |
| 6835802 | Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties Methods of synthesizing a substantially monodispersed mixture of polymers comprising polyethylene glycol moieties include: reacting a substantially monodispersed mixture of compounds having the structure of Formula I: R | 12/28/2004 |
| 6828305 | Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same Mixtures of conjugates in which each conjugate in the mixture comprises a growth hormone drug coupled to an oligomer that includes a polyalkylene glycol moiety wherein the mixtures have a molecular weight distribution with a standard deviation of less than about 22 ... | 12/07/2004 |
| 6828297 | Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same A mixture of conjugates in which each conjugate in the mixture comprises an insulin drug coupled to an oligomer that includes a polyalkylene glycol moiety is disclosed. The mixture may exhibit higher in vivo activity than a polydispersed mixture of similar conjugate... | 12/07/2004 |
| 6815530 | Substantiallymonodispersed mixtures of polymers having polyethylene glycol moieties Methods of synthesizing a substantially monodispersed mixture of polymers comprising polyethylene glycol moieties include: reacting a substantially monodispersed mixture of compounds having the structure of Formula I: R | 11/09/2004 |
| 6812362 | Methods of synthesizing acylanilides including bicalutamide and derivatives thereof Methods of synthesizing an acylanilide include contacting a compound having the structure of Formula I: with a compound having the structure of Formula II: under conditio... | 11/02/2004 |
| 6770625 | Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith Pharmaceutical compositions that include a drug-oligomer conjugate, a fatty acid component, and a bile salt component are described. The drug is covalently coupled to an oligomeric moiety. The fatty acid component and the bile salt component are present in a weight-... | 08/03/2004 |
| 6730701 | 6-methoxy-2-naphthylacetic acid prodrugs The present invention provides compositions useful for the treatment of inflammation in humans, and related methods of treatment for the same. In one embodiment the composition is: In another embodiment, the composition ... | 05/04/2004 |
| 6713452 | Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same A mixture of conjugates in which each conjugate in the mixture comprises a calcitonin drug coupled to an oligomer that includes a polyalkylene glycol moiety is disclosed. The mixture may lower serum calcium levels in a subject by 10, 15 or even 20 percent or more. M... | 03/30/2004 |
| 6713510 | 6-Methoxy-2-naphthylacetic acid prodrugs The present invention provides compositions useful for the treatment of inflammation in humans, and related methods of treatment for the same. In one embodiment the composition is In another embodiment, the composition i... | 03/30/2004 |
| 6703381 | Methods for delivery therapeutic compounds across the blood-brain barrier The present invention relates to amphiphilic drug-oligomer conjugates capable of traversing the blood-brain barrier ("BBB") and to methods of making and using such conjugates. An amphiphilic drug-oligomer conjugates comprise a therapeutic compound conjuga... | 03/09/2004 |
| 6653348 | 6-methoxy-2-naphthylacetic acid prodrugs The present invention provides compositions useful for the treatment of inflammation in humans, and related methods of treatment for the same. In one embodiment the composition is ##STR1## In another embodiment, the composition is ##STR2## Additional... | 11/25/2003 |
| 6610739 | 6-methoxy-2-naphthylacetic acid prodrugs The present invention provides compositions useful for the treatment of inflammation in humans, and related methods of treatment for the same. In one embodiment the composition is ##STR1## In another embodiment, the composition is ##STR2## Additional... | 08/26/2003 |
| 6593492 | Resolution of intermediates in the synthesis of substantially pure bicalutamide A methods of preparing a substantially pure enantiomer of an acylanilide such as Casodex.RTM. (bicalutamide) and/or its derivatives includes resolving an intermediate compound having the structure of Formula I: ##STR1## wherein R1 is alkyl or h... | 07/15/2003 |
| 6583306 | Methods of asymmetrically synthesizing enantiomers of Casodex, its derivatives and intermediates thereof Methods of synthesizing pure enantiomers of acylanalides such as Casodex.RTM. (bicalutamide) and its derivatives utilizing a compound having a ring structure that, when opened, provides a substituent having the structure of Formula I: ##STR1## wherei... | 06/24/2003 |
| 6583128 | Immunoregulatory compounds and derivatives and methods of treating diseases therewith Compounds are disclosed having the structure of Formula I: ##STR1## where R1, R3, and R4 are independently hydrogen or C1 to C4 alkyl, and R2 is: ##STR2## where R5 is selected fr... | 06/24/2003 |
| 6541508 | Taxane prodrugs Taxane prodrugs comprise a taxane joined by a hydrolyzable bond to one or more oligomers that comprise a polyethylene glycol moiety. The oligomer preferably further comprises a salt-forming moiety.... | 04/01/2003 |
| 6525098 | 6-methoxy-2-naphthylacetic acid prodrugs The present invention provides therapeutically effective amounts of 6MNA prodrugs. The pharmaceutical composition comprises ##STR1## wherein R is H or COR', wherein R' is selected from the group consisting of C1 to C6 alkyl, (CH... | 02/25/2003 |
| 6479692 | Methods of synthesizing acylanilides including bicalutamide and derivatives thereof Methods of synthesizing an acylanilide ##STR1##... | 11/12/2002 |
| 6458776 | 5-ASA derivatives having anti-inflammatory and antibiotic activity and methods of treating diseases therewith Compounds are disclosed represented by the following formula: ##STR1## where R1 is a substituted or unsubstituted phenyl group, and where Z is selected such that a compound, Z-R1 -NH2, formed by cleavage of the azo bond is... | 10/01/2002 |
| 6436990 | 6-methoxy-2-naphthylacetic acid prodrugs The present invention provides compositions useful for the treatment of inflammation in humans, and related methods of treatment for the same. In one embodiment the composition is ##STR1## In another embodiment, the composition is ##STR2## In yet ano... | 08/20/2002 |
